IL1B and type 2 diabetes mellitus: As our antibodies primarily recognize and remove extracellular aggregates, our data suggest that a large fraction of the aggregates is localized in the extracellular space and that removal of these extracellular aggregates alone is sufficient to improve symptoms of T2DM, including a decrease in glucose level and reduced production of the pro-inflammatory cytokine IL-1β.